23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
The analysis of strategic alternatives will include an assessment of various possible scenarios, including but not limited to raising additional capital or attracting a strategic investor ...
The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special ...
Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback